Hadasit Bio-Holdings Ltd (HSITF) Research

Hadasit Bio-Holdings Ltd, an Israeli biotechnology enterprise established in Jerusalem in 2005, focuses its efforts on critical therapeutic domains. These include oncology, regenerative medicine, and inflammatory diseases. A key offering is ProtAb, an immunotherapeutic monoclonal antibody engineered to treat autoimmune inflammatory disorders.

Market snapshot

Symbol
HSITF
Price
$0.12
Day change
0.00%
Market cap
$3.9M
P/E ratio
-2.71x
52-week range
0.12-0.13
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • AccuStem Sciences Limited (ACMSY)
  • Cell Source, Inc. (CLCS)
  • CareView Communications, Inc. (CRVW)
  • Gemina Laboratories Ltd. (GLABF)
  • Institute of Biomedical Research Corp. (MRES)
  • Propanc Biopharma, Inc. (PPCB)
  • Quest PharmaTech Inc. (QPTFF)
  • Synairgen plc (SYGGF)

Open Hadasit Bio-Holdings Ltd (HSITF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.